ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies

ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies

In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions, has secured an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop a Parsortix-based Androgen Receptor (AR) detection assay for prostate cancer studies. The assay will be developed in ANGLE’s UK laboratories, and its successful […]

ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology

ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology

ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant supplier agreement with global biopharmaceutical leader AstraZeneca PLC. The collaboration focuses on developing a novel methodology for the detection of micronuclei in CTCs, utilizing ANGLE’s DNA damage response (DDR) assay, a key marker in cancer diagnostics and […]

ANGLE plc announces cancer diagnosis breakthrough with DNA molecular analysis

ANGLE plc announces cancer diagnosis breakthrough with DNA molecular analysis

ANGLE plc, a global leader in liquid biopsy technology, has recently achieved a major breakthrough in cancer diagnostics, unveiling results from DNA molecular analysis of patient blood samples. These results provide an unprecedented insight into the individual progression of cancer and open new avenues for treatment. Revolutionizing Cancer Diagnostics with Parsortix System ANGLE’s expansion of […]